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Summary
Heavy metals are omnipresent in the environment, and industrial use has greatly increased their
presence in soil, water and air. Their inevitable transfer to the human food chain remains an
important environmental issue as many heavy metals cause a range of toxic effects, including
developmental toxicity. Administration of chromium VI (1 and 2 mg/kg as potassium dichromate)
through intraperitoneal (i.p.) injection during organogenesis (days 6 to 15 of gestation) in rats revealed
embryo- and fetotoxic effects. Reduced fetal weight, retarded fetal development, number of fetuses per
mother and high incidences of dead fetuses and resorptions in treated mothers were also observed. Gross
morphological abnormalities, such as displayed form of edema, facial defect, lack of tail, hypotrophy,
severs subdermal haemorrhage patches and hypotrophy of placenta were observed in fetuses after
chromium VI-treated mothers. A skeletal development of fetuses presented an incomplete ossification
in nasal, cranium, abdominal or caudal bones in rats treated with 1 mg/kg of chromium, whereas
rats treated with 2 mg/kg showed ossification and absence of the sacral vertebrae compared with the
control. At a higher dose of chromium, histological changes were found in fetuses with atrophy of theirs
vital organs. Placental histological observations revealed a pronounced morphological alteration, with
atrophy of decidual cells, a degenerated of chorionic villi and hypertrophy of blood lacuna. The present
study suggests a risk to the developing embryo when the mother is exposed to a high concentration of
chromium VI during organogenesis.
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Introduction
One example of heavy metals is chromium, which
is a naturally occurring element found in rocks,
plants, animals, volcanic soils dust and gases (Nriagu
et al., 1988). Chromium is extensively used in
metallurgical processes, such as chrome plating,
pigment production, tanning, textile, ceramic, glass
and photographic industries. Chromium occurs in
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the workplace predominantly in two valency states:
hexavalent chromium (chromium VI) and trivalent
chromium (chromium III). The hexavalent form is
usually linked with oxygen and is a strong oxidizing
agent. It is widely known to cause allergic dermatitis,
as well as toxic and carcinogenic effects in humans and
animals (Norseth, 1981; Von Burg et al., 1993; Domingo,
1994; Stohs et al., 1995, Kawanishi et al., 2002). High
levels of chromium are reported to impair gestational
development as evidenced by epidemiological studies
in female workers exposed to this metal in the
work environment (Shmitova, 1978, 1980). Exposure to
chromium VI can induce complications during preg-
nancy and child birth (Shmitova, 1978, 1980). It was
reported that chromium VI induces developmental
effects include post-implantation losses, resorptions,
reduced fetal weight and malformations including
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reduced ossification (E.P.A., 1998; Wilbur et al.,
2000; European Commission, 2005). A previous study
(Pribluda, 1963) reported the transfer of chromium
from the mother to the fetus bones in human. Pribluda
(1963) demonstrated that the chromium content of
bones of pregnant rats decreases with advancing
gestation. Such released chromium may reach the
circulatory system and enter feto-placental tissues
through the placental barrier. However, the toxic
effects of chromium VI on embryo-fetal development
in rats are still unclear. The present study was carried
out to determine the effect of chromium VI given
through intraperitoneal injection during the period
of organogenesis during embryogenesis and fetal
development, as well as its effects on various regions
of fetuses bone. Moreover, the morphology and the
histology of placenta and fetuses were investigated.
Materials and methods
Animals and reagents
Two-month-old Wistar female rats (150 g) were used
in this study. Rats were housed under controlled
conditions of temperature (22 ± 1◦C), with a 14-h
light/dark cycle. Female rats of proven fertility were
kept for mating (2:1) with normal healthy adult males
overnight. The day at which sperms were found in the
vaginal smear was designated as day 0 of gestation.
These pregnant females were divided into three equal
groups (n = 8) of approximately similar weight
as follows: (1) animals received an intraperitoneal
injection (i.p.) of potassium dichromate [(K2Cr2O7)
purchased from Hopkin and Williams Searle Co.,
London, England] diluted with NaCl solution 9% at
dose of 1 mg/kg body weight (b.wt); (2) animals
were administered 2 mg of potassium dichromate/kg
b.wt; and (3) the control group received equal volumes
of vehicle, from days 6 to 15 of gestation. The
animals were kept in polycarbonate cages individually
and were given feed and water ad libitum. The dams
were observed daily for change in body weight and
physical signs of toxicity, if any. After 19 days of
gestation, all animals were killed by decapitation; the
number of fetuses/litter, number of live/dead fetuses,
crown-rump length, number of resorptions, number
of implantations, weight of uteri, of fetuses and their
respective placenta were recorded. Post-implantation
loss was calculated on the basis of previous report (Lee
et al., 2009):
post-implantation
= [(total implantations − live fetuses)/
total implantations] × 100.
Morphological evaluation of the offspring
The left and the right uterine horns were removed
and the rat was terminated. The first implantation
site next to the ovary was denoted following the
convention position 1 in order to the last position
in the uterine horn next to the cervix. Each em-
bryo, from right and left uterine horn regarding
to intrauterine position, was removed to examine
the gross malformations. Structural deviations from
normal development were considered as denoted
malformations, i.e. facial defects, body malrotation and
neural tube defects. Malformed and non-malformed
offspring were subsequently examined for skeletal
anomalies. A skeletal radiographic (General Electric;
voltage 27 kV, intensity 5 mA) was done to observe
the effect of chromium VI on various regions of
bone (nasal bone, cranium, abdominal, caudal) in
fetuses.
Histological analysis
Placenta and fetuses were fixed overnight at room
temperature by direct immersion in 4% paraformalde-
hyde in 0.1 M phosphate buffer, pH 7.4. The samples
were dehydrated with an ethanol and toluene series
and embedded in paraffin. Serial sections (4μm) were
mounted on gelatin-coated glass slides cut and stained
with haematoxylin and eosin.
Statistical analysis
Data were analysed using Stat View 512+ software
(Abacus Concept). The results were expressed as
means ± SE and a comparison of two means was made
using Student’s t-test.
Results
No notable changes in behaviour or clinical signs were
observed in the control or in the treated dams. No mor-
tality was observed during the experimental period.
The dams treated with 1 and 2 mg of chromium/kg
b.wt day-1 presented a significant reduction in body
weight gain during treatment period (Table 1). This
decrease was about 29% and 60% compared with the
control group. The relative weight of uterus was also
decreased after i.p. injection of chromium during the
organogenesis period, this decrease reached 21% and
30% of controls for 1 and 2 mg of chromium/kg
b.wt day-1, respectively. The number of fetuses/ litter
was significantly reduced in treated groups when
compared with controls (6.43 ± 0.75 and 6.29 ± 1.13
respectively with 1 and 2 mg of chromium/kg b.wt
versus 9.75 ± 0.37). Fetal weight and crown rump
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Table 1 Chromium-induced embryotoxicity and fetotoxicity in rats treated during organogenesis
+ Chromium
Control 1 mg/kg 2 mg/kg
Weight gain in mother (g) 83 ± 2.45 58.8 ± 1.81b 33 ± 11.48b
Relative weight of uterus (g/100g) 2.03 ± 0.02 1.60 ± 0.20a 1.42 ± 0.22a
No. of fetuses (dead and live)/ litter 9.75 ± 0.37 6.43 ± 0.75b 6.29 ± 1.13b
No. of dead fetuses (no. of litters) All live 2 (2) 7 (4)
Fetal weight (g) 3.86 ± 0.04 3.06 ± 0.13a 2.61 ± 0.15b
Placental weight (g) 0.58 ± 0.006 0.52 ± 0.01a 0.41 ± 0.01b
Crown rump length (cm) 3.71 ± 0.05 2.92 ± 0.08a 2.76 ± 0.08b
No. of resorption sites 0.13 ± 0.12 0.29 ± 0.28 0.42 ± 0.20a
No. of implantations 9.88 ± 0.30 6.72 ± 0.57a 6.71 ± 1.04a
Post implantation loss (%) 1.39 ± 1.38 9.08 ± 5.56a 23.92 ± 6.52b
Values represent mean ± standard error (SE) of 8 rats in each group. Chromium treatment was
preformed as described in the Methods section.
ap < 0.05 compared with controls (Student’s t-test).
bp < 0.001 compared with controls (Student’s t-test).
Figure 1 Type of malformations in fetuses of pregnant rats in 19 days of gestation. Rats received an i.p. injection of 2 mg/kg
body weight of potassium dichromate during the organogenesis period. (A) Normal; (B, C) edema; (C, D) facial defect, lack of
tail and severe subdermal haemorrhage patches; (E) hypotrophy and presence of haemorrhage areas (arrowed).
length were also significantly decreased in groups
treated with chromium. This decrease was about 20.7%
and 32.4% in fetal weight and 21.3% and 25.6% in
crown rump length respectively in rats treated with
1 and 2 mg of chromium/kg compared with the
control. Our data indicate that the placenta weight
was significantly reduced in groups treated with
chromium (0.52 ± 0.01 and 0.41 ± 0.01 respectively
with 1 and 2 mg of chromium/kg b.wt versus 0.58 ±
0.006). The incidences of dead fetuses were high
in groups treated with chromium compared with
the control group. The number of resorption sites
was found to be dose dependent. The higher dose
caused more incidences of resorption sites than the
lower one (0.29 ± 0.28 and 0.42 ± 0.20 respectively
with 1 and 2 mg of chromium/kg b.wt versus
0.13 ± 0.12). The i.p. injection of chromium during
the organogenesis period decreases significantly the
number of implantations. This decrease was about
31.9% and 32% respectively in rats treated with 1 and
2 mg of chromium/kg compared with the control.
Controversy, the data revealed significantly higher
incidences of post implantation loss in treated groups
(9% and 24%, respectively with 1 and 2 mg of
chromium/kg b.wt) (Table 1).
Gross structural abnormalities in the form of edema
and subdermal haemorrhagic patches were observed
on the thoracic and abdominal regions in fetuses of
pregnant rats treated with 1 mg of chromium/kg
when compared with controls (data not shown).
The changes were more significant in groups treated
with a high dose of chromium (2 mg/kg) compared
with the preceding lower-dose group. Morphological
study of the fetuses, from treated rats with 2 mg
of chromium/kg, showed gross malformations like
edema, facial defect, lack of tail, hypotrophy and
severe subdermal haemorrhage patches compared
with the control (Fig. 1).
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Figure 2 Title: A skeletal radiographic of fetuses from control (A) and chromium-treated rats with 1 mg/kg (B) and 2 mg/kg
(C) during the organogenesis period. (A) Fetuses showed the presence of four sacral vertebrae (a: nasal bones, b: cranium
bones, c: abdominal bones, d: caudal bones). (B) Fetuses showed incomplete ossification (arrowed). (C) Fetuses showed the
absence of any vertebrae.
Figure 3 Photomicrographs of sections of fetuses from control (A) and chromium-treated rats with 2 mg/kg (B) during the
organogenesis period. Fetuses were fixed by direct immersion in paraformaldehyde solution. Serial (5μm) sections were
mounted on gelatin coated glass slides and stained with hematoxylin and eosin. (a) Heart; (b) lung; (c) sacral vertebrae;
(d) liver.
A skeletal development of fetuses, presented in
Fig. 2, showed dose-related effects. In the 1 mg/kg-
treated group, fetuses presented only an incomplete
ossification in nasal, cranium, abdominal or caudal
bones compared with the control. Whereas, the most
striking abnormality seen in X-rays was absence
of ossification of the sacral vertebrae: this situation
occurred in the fetuses from the pregnant rats injected
with 2 mg of chromium/kg during the organogenesis
period. Light microscopic inspection of fetuses from
rats treated with a high dose of chromium revealed
an atrophy of organs such as liver, lung, heart
and skeletal compared with the control (Fig. 3).
Placentas from dams given K2Cr2O7 during the
organogenesis period showed some morphological
alterations when compared with the control group
(Fig. 4). The placentas exhibited dose-dependant
hypotrophy macroscopically in rats injected with
chromium 1 and 2 mg/kg. Histopathologically, in
the treated group, increased dose-dependant thickness
was noted significantly in the decidua basalis with
atrophy of decidual cells. Furthermore, we observed
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Figure 4 Gross appearance of the placenta of the control (A) and chromium-treated group with 1 mg/kg (B) and 2 mg/kg
(C). Rats received an i.p. injection of 1 and 2 mg/kg body weight of potassium dichromate during organogenesis period. (B,C)
Marked hypotrophy in the chromium-treated placenta.
Figure 5 Photomicrographs of sections of placenta from control (A) and chromium-treated rats with 1 mg/kg (B) and 2 mg/kg
(C) during the organogenesis period. Placentas were fixed by direct immersion in paraformaldehyde solution. Serial (5μm)
sections were mounted on gelatin-coated glass slides and stained with hematoxylin and eosin. DB, decidua basalis; DC,
decidual cells; BL, blood lacunas; CV, chorionic villi. Magnification: ×200 (A–C).
degeneration of chorionic villi and hypertrophy of
blood lacuna that was particularly remarkable in
groups treated with a high dose (Fig. 5).
Discussion
Chromium VI is generally considered to be a
carcinogen and mutagen because of its ability to
be transported into cells (via oxyanion transporters).
Chromium VI is teratogenic and acts without an
intermediate (E.P.A., 1998; Wilbur et al., 2000; European
Commission, 2005). Moreover, chromium VI is known
to be also teratogenic in mice (E.P.A., 1998; Schardein,
2000; Wilbur et al., 2000; European Commission, 2005),
which should exclude possible problems of species
variation in the embryonic cell test (EST), which
is based on murine cell lines. On the other hand,
chromium III and chromium VI are considered not
to be embryotoxic, but other chromium hexavalent
compounds are considered to have similar toxicity
effects in humans (Wilbur et al., 2000).
In the present study, chromium VI i.p. injection
revealed fetal development retardation and embryo
fetotoxicity as evidenced by the reduction in fetal
weight, crown rump length, number of fetuses
per dam, number of implantations and higher
incidences of resorptions sites, embryonic death and
post-implantation loss in animals treated with 1 and
2 mg/kg of chromium. Furthermore, our results
indicated that the treatment of pregnant rats with
chromium induced a decrease in weight gain in mother
and in their uterus’s relative weight. Our findings
were in accordance with other studies carried out
in pregnant rats and have demonstrated that the
administration of chromium VI via drinking water
causes fetotoxic effects with significant reduction of
implantation rate, number of fetuses and an increase
in the resorptions number, preimplantation and post-
implantation loss for mothers treated with chromium
(Junaid et al., 1996a; Kanojia et al., 1996, 1998).
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The decrease in maternal and fetus weight gain
during exposure to chromium may be attributed to
alteration of maternal physiology because of high
blood chromium levels (Kanojia et al., 1998). On the
other hand, poor nutrition in pregnant rats leads to
intra-uterine growth retardation, post-natal growth
failure, changes in the endocrine parameters of the
somatotrophic axis, and to increased blood pressure in
later life (Woodall et al., 1996; Gluckman et al., 1997;
Battista et al., 2002). The relationship between maternal
and developmental toxicity is important in making
regulatory decisions regarding the developmental
toxicity of a chemical.
Accordingly, a systematic and critical approach is
needed to characterize the role of maternal toxicity in
laboratory animal studies with adverse developmental
outcome (Iyer et al., 1999).
The decrease in maternal weight gain during
pregnancy clearly indicated that chromium VI was
maternally toxic. A possible explanation might be the
chromium induced inhibition of cell growth by specific
blocking of the progression of cells through the S-
phase of the cell cycle (Xu et al., 1996). Previous study
(Kanojia et al., 1996) reported that the development
of the embryo during gestation was impaired when
chromium was administered for 20 days prior to
gestation. Gale (1982) injected 8 mg chromium trioxide
per kg intravenously in hamsters on day 8 of gestation
and found increased incidence of cleft palate.
The present study showed clearly that chromium
exposure through i.p. injection to pregnant rats
during the period of organogenesis revealed marked
teratological changes in treated fetuses.
The malformed offspring in the uterine harms of
treated animals displayed a form of edema, facial
defect, lack of tail, hypotrophy and severe subdermal
haemorrhage patches compared with the control.
Histopathologically, the malformed fetuses showed
an atrophy of vital organs such as liver, lung and
heart compared with the control. These findings
could be explained by the reduction in the uterine
vascularization, which induced less blood flow to
the implantation sites, consequently inducing fetal-
placental growth retardation (Garris, 1984). It was
reported that acute interruption of blood flow to the
uterine horn was shown to be teratogenic in the rat
embryo on gestational days 8–10 (Franklin et al., 1960).
On the other hand, studies reported that interrupted
uterine blood flow caused growth retardation and fetal
mortality, but not somatic malformations (New et al.,
1977; Garris, 1984).
Even more interesting, at these stages when the
skeleton could be observed, was the presence of many
abnormalities with incomplete or absent ossification of
sacral vertebrae, which demonstrated that chromium
is responsible for the observed vertebral anomalies.
Our results were in accordance with other studies
carried out in pregnant mice and have demonstrated
that the administration of chromium picolinate, from
gestation days 6 to 17, causes a significant increase
of the incidence of bifurcated cervical arches in
fetuses from treated groups (Bailey et al., 2006).
Sankaramanivel et al. (2006) revealed that treatment
of rats with chromium i.p. (0.5 mg/kg), in the form
of potassium dichromate for 5 days, provoked an
accumulation of chromium 5.2-fold in the vertebrae,
8.9-fold in the femur and 8.7-fold in the calvaria,
when compared with control. In vertebrae and calvaria
these authors also demonstrated that chromium ad-
ministration reduced enzymatic activities significantly
e.g. alkaline phosphatase (ALP) and tartrate-resistant
acid phosphatase (TRAP) and significantly increased
calcium concentration, altered bone formation rate and
bone morphology in the femur. However, fetal growth
is greatly associated with placental development. The
placenta is a highly specialized tissue supported by
several cell systems involved in both its structure and
function in fetal–maternal exchange that suggests a
role in regulation of fetal growth during pregnancy.
In the present study, we observed that chromium VI
caused histological alterations in placenta, such as
thickness of decidua basalis, atrophy of decidual cells,
a degeneration of chorionic villi and hypertrophy of
blood lacuna. Therefore, the retention of chromium
in placenta in the treated group have impaired
placental physiology resulting in embryo and fetotoxic
effects as evidenced by various heavy metals (Hg,
Cd) and other xenobiotics (Miller). Chromium VI
is more easily transferred to the embryo and fetus
(Tipton, 1960; Danielsson et al., 1982). It was reported
that chromium VI can produce teratogenic effects,
probably due to the higher embryonic concentration
(Danielsson et al., 1982). Danielsson et al. (1982) have
studied the concentration of chromium in embryo
and fetus in early and late gestational stages of mice
and reported high chromium in the placenta and
increased passage to the fetus, and directly affected
the embryonic structures. The toxicity of chromium
VI is due to its partial conversion to chromium III in
the gastrointestinal tract. Coogan et al. (1991) reported
higher levels of chromium VI than chromium III in
tissues, which reflects the greater ability of chromium
VI to cross the plasma membrane and bind to the
intracellular protein in various tissues; this might
explain the greater degree of toxicity of chromium VI.
Embryonic and fetal levels of chromium VI in pregnant
rats after exposure to chromate are reported to be ten
times more toxic (Danielsson et al., 1982) than those of
chromium III after exposure to corresponding doses of
chromium III.
The present study indicates that sufficiently high
chromium VI intake through i.p. injection during the
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period of organogenesis may cause a risk to the
developing embryo and fetus. However, to elucidate
his pathway of action require further studies.
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